Alliances
A start-up specialising in digital healthtech has announced a major strategic collaboration with its Malaysian counterpart, which will help propel the promising British SME to the next level.
The deal will last three years, with a top priority to develop a gene therapy for hemophilia A.
Haselmeier and Stevanato Group announced an exclusive agreement to license the Axis-D pen-injector technology and intellectual property for Development, Manufacturing and Supply of the Axis-D pen-injector in the Therapeutic Area of Diabetes Care.
Akcea and Ionis to earn $250 million license fee
ProBioGen AG and Ceva Santé Animale announce the signature of an exclusive license agreement for the manufacture of vectorised poultry vaccines using ProBioGen’s proprietary AGE1.CR® technology.
Sensyne Health plc, the British clinical AI technology company, announced it has entered into a formal research agreement with the UK MHRA to contribute to the development of methods to validate software algorithms used in digital health.
The two companies will partner on the process development, analytical development and large-scale manufacturing for late-stage clinical and commercial supply.
Under the terms of the deal, 4D will use its proprietary MicroRx platform with Merck’s expertise in novel vaccine development and commercialization to discover and develop Live Biotherapeutics as vaccines in up to three currently undisclosed indications.
Company also announces participation in BioJapan 2019, one of Asia’s largest partnering events for the global biotechnology industry, October 9-11, 2019 in Pacifico Yokohama
PDS0101- KEYTRUDA® (pembrolizumab) Combination to be Evaluated in First Line Treatment of Metastatic Head and Neck Cancer
PRESS RELEASES